Order Back Issue
| Issue No. |
Issue Name |
Published On |
| 587 |
Phase 3 Failure, but Group Still Strong
|
Sep. 27, 2007 |
| 585 |
Immtech — Time for a New Rec
|
Sep. 13, 2007 |
| 578 |
Sum of Parts—More than Meets the Eye
|
Jul. 19, 2007 |
| 575 |
A Look Back at ADA
|
Jun. 28, 2007 |
| 573 |
ARQL—A New Recommendation
|
Jun. 14, 2007 |
| 572 |
ASCO Follow-Up
|
Jun. 7, 2007 |
| 570 |
ASCO Preview
|
May. 24, 2007 |
| 565 |
Update April 19 2007
|
Apr. 19, 2007 |
| 564 |
Carbohydrate Drugs
|
Apr. 5, 2007 |
| 563 |
ACC Preview
|
Mar. 15, 2007 |
| 562 |
Drug Development—Current Events
|
Mar. 1, 2007 |
| 561 |
Follow-on biologics
|
Feb. 15, 2007 |
| 560 |
Short-selling—'sell high, buy low'
|
Feb. 1, 2007 |
| 559 |
Outlook for 2007
|
Jan. 18, 2007 |
| 558 |
The Best Times to Own Biotech Stocks
|
Jan. 4, 2007 |
| 557 |
2006—A Look Back
|
Dec. 14, 2006 |
| 556 |
ASH Preview
|
Nov. 30, 2006 |
| 555 |
Investing in Weight Loss
|
Nov. 9, 2006 |
| 554 |
Mergers & Acquisitions
|
Oct. 26, 2006 |
| 553 |
Peramivir's Second Life
|
Oct. 12, 2006 |
| 552 |
Cardium A Hidden SmallCap Gem
|
Sep. 28, 2006 |
| 551 |
Selling Pharmaceuticals : A Worldwide Perspective Part III
|
Sep. 14, 2006 |
| 550 |
Pancreatic Cancer
|
Aug. 31, 2006 |
| 549 |
Selling Pharmaceuticals : A Worldwide Perspective Part II
|
Aug. 17, 2006 |
| 548 |
Selling Pharmaceuticals: A Worldwide Perspective Part I
|
Aug. 3, 2006 |
| 547 |
Mid- Year Review
|
Jul. 20, 2006 |
| 546 |
ADA re-cap
|
Jun. 29, 2006 |
| 545 |
Post-ASCO Review
|
Jun. 15, 2006 |
| 544 |
A Look Back at DDW
|
Jun. 1, 2006 |
| 543 |
ASCO Preview
|
May. 18, 2006 |
| 542 |
What is happening in the biotech sector
|
May. 4, 2006 |
| 541 |
ARNA—a new recommendation
|
Apr. 20, 2006 |
| 540 |
Stroke
|
Apr. 6, 2006 |
| 539 |
Tysabri: One year later
|
Mar. 23, 2006 |
| 538 |
A Case of (for) the small or mid-caps
|
Mar. 9, 2006 |
| 537 |
ACC Coming— Update on MDCO
|
Feb. 23, 2006 |
| 536 |
Treating BPH—Expanding Cialis Sales
|
Feb. 2, 2006 |
| 535 |
Outlook for 2006
|
Jan. 19, 2006 |
| 534 |
ASH Review
|
Jan. 5, 2006 |
| 533 |
2005—A Look Back
|
Dec. 15, 2005 |
| 532 |
HCV Update
|
Dec. 1, 2005 |
| 531 |
AMD—Better Treatments “In Sight”
|
Nov. 17, 2005 |
| 530 |
Psoriasis-Treatment Updates
|
Nov. 3, 2005 |
| 529 |
Treating HIV Resistance
|
Oct. 21, 2005 |
| 528 |
Boning Up - Osteoporosis
|
Oct. 6, 2005 |
| 527 |
Treating Diabetes—Progress Accelerates
|
Sep. 22, 2005 |
| 526 |
Avian Flu
|
Sep. 8, 2005 |
| 525 |
Lupus—Help On The Horizon
|
Aug. 25, 2005 |
| 524 |
Mergers and Acquisitions
|
Aug. 11, 2005 |
| 523 |
NeoPharm: Hope for Brain Cancer Patients
|
Jul. 28, 2005 |
| 522 |
Mid-Year Review
|
Jul. 14, 2005 |
| 521 |
Treating Brain Cancer
|
Jun. 30, 2005 |
| 520 |
SONUS— An In Depth Look
|
Jun. 16, 2005 |
| 519 |
Reflections on ASCO
|
May. 26, 2005 |
| 518 |
ASCO—Genentech & the Rest
|
May. 12, 2005 |
| 517 |
Biogen Idec—A Closer Look
|
Apr. 28, 2005 |
| 516 |
New Treatments for Rheumatoid Arthritis
|
Apr. 14, 2005 |
| 515 |
GenVec—Genes to Drugs
|
Mar. 31, 2005 |
| 514 |
ACC Review
|
Mar. 17, 2005 |
| 513 |
Treating Multiple Sclerosis
|
Mar. 3, 2005 |
| 512 |
Treating Insomnia
|
Feb. 17, 2005 |
| 511 |
Drug-Eluting Stents
|
Feb. 3, 2005 |
| 510 |
Outlook for 2005
|
Jan. 20, 2005 |
| 509 |
The FDA and the Myth of Safe Drugs
|
Jan. 6, 2005 |
| 508 |
Review of 2004
|
Dec. 16, 2004 |
| 507 |
Prescription Drugs--Who's Going to Pay
|
Dec. 2, 2004 |
| 506 |
The Flap Over Flu Vaccines
|
Nov. 18, 2004 |
| 505 |
Evolving Partnerships
|
Nov. 4, 2004 |
| 504 |
Cancer Topics
|
Oct. 21, 2004 |
| 503 |
Got Bone
|
Oct. 7, 2004 |
| 502 |
Cardiovascular Update
|
Sep. 23, 2004 |
| 501 |
Issues in HIV-AIDS
|
Sep. 9, 2004 |
| 500 |
Learning from the Past, Investing in the Future
|
Aug. 26, 2004 |
| 500 |
Sample_Learning from the Past, Investing in the Future
|
Aug. 26, 2004 |
| 499 |
Sample_Treating Hematological Cancers
|
Aug. 12, 2004 |
| 499 |
Treating Hematological Cancers
|
Aug. 12, 2004 |
| 498 |
Mid-Year Report
|
Jul. 29, 2004 |
| 498 |
Sample_Mid-Year Report
|
Jul. 29, 2004 |
| 497 |
Valuing Biotech Companies Before They Turn Profit
|
Jul. 15, 2004 |
| 496 |
Revisiting Diabetes
|
Jul. 1, 2004 |
| 495 |
Reflections on ASCO
|
Jun. 17, 2004 |
| 494 |
Partnerships
|
Jun. 3, 2004 |
| 493 |
Looking Ahead to ASCO
|
May. 20, 2004 |
| 492 |
Age-Related Macular Degeneration
|
Apr. 29, 2004 |
| 491 |
Overactive Bladder
|
Apr. 15, 2004 |
| 490 |
Mergers and Aquisitions
|
Apr. 1, 2004 |
| 489 |
Genentech--Sustaining Excellence
|
Mar. 18, 2004 |
| 488 |
Women's Cancers
|
Mar. 4, 2004 |
| 487 |
Inflammatory Bowel Disease
|
Feb. 19, 2004 |
| 486 |
New Life for Radiation Therapy
|
Feb. 5, 2004 |
| 485 |
Outlook for 2004
|
Jan. 22, 2004 |
| 484 |
FDA Report Card, 2003
|
Jan. 8, 2004 |
| 483 |
Review of 2003
|
Dec. 18, 2003 |
| 481 |
Hepatitis C
|
Nov. 20, 2003 |
| 480 |
BioCryst--Alabama Orphan
|
Nov. 6, 2003 |
| 479 |
Big Bio--All in the Family
|
Oct. 23, 2003 |
| 478 |
Osteoporosis--The Silent Disease
|
Oct. 9, 2003 |
| 477 |
Biologics to Treat Psoriasis
|
Sep. 25, 2003 |
| 476 |
The PDE5 Inhibition Wars
|
Sep. 11, 2003 |
| 00 |
s a m p l e
|
Jan. 1, 2005 |
|
What Do People Say About MTSL?
'Please accept my thanks for providing the help that even those of us whose careers are in biotechnology require to navigate towards investment success. I look forward to future issues and to a long relationship with The Medical Technology Stock Letter.'
Arnold D. Gale, M.D., FAAP
| |
'After reading hundreds of financial newsletters every week for over 20 years, I can tell you that the Medical Technology Stock Letter is one of just a small handful of newsletters that I consider a must-read for all serious growth investors. In terms of knowledge, expertise and advice on biotechnology stocks, John McCamant is quite simply the very best in the business.'
Steven Halpern
Publisher and Editor of thestockadvisors
|
|
